InvestSMART

Neurizon Therapeutics Limited (ASX: NUZ) - Share Price

- Current share price for NUZ : $0.066

Neurizon Therapeutics Limited (NUZ), an ASX-listed company, is engaged in the development of its own drug discovery intellectual property for the treatment of neurological diseases.

NUZ General Information +

ASX Code NUZ
Website N/A
Industry/Sector Pharmaceuticals
Market Cap ($M) 50
NUZ Share Price $0.066
Day High $0.066
Day Low $0.066
Last Close $0.066
NUZ Share Price Movement - ( No change )
Prices as at 10:36, 9 Jul 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

Neurizon Therapeutics Limited (NUZ) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield

See all dividends from Neurizon Therapeutics Limited (NUZ) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Neurizon Therapeutics Limited (NUZ) price-sensitive announcements

NUZ - Neurizon executes long-term supply agreement with Elanco
Neurizon Therapeutics Limited has executed a strategic long-term supply agreement with Ela
Neurizon Therapeutics Limited (NUZ)
17 Jun 2026 | 9:07 AM
NUZ - HEALEY ALS Trial Surpasses 50% Dosing Ahead of Schedule
Neurizon Therapeutics Limited announced that they have surpassed the 50% dosing milestone
Neurizon Therapeutics Limited (NUZ)
12 Jun 2026 | 9:07 AM
NUZ - HEALEY ALS Trial Regimen I Expands to 240 Participants
Neurizon Therapeutics Limited, a biotech company focused on neurodegenerative diseases, ha
Neurizon Therapeutics Limited (NUZ)
27 May 2026 | 9:20 AM
NUZ - Ethics Approval Received for NUZ-001 Oral Liquid P1 Study
Neurizon Therapeutics Limited has received ethics approval from the Bellberry Human Resear
Neurizon Therapeutics Limited (NUZ)
13 May 2026 | 9:19 AM

Neurizon Therapeutics Limited (NUZ) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+
Price at
release+
Current
price+
Gain/Loss View
Neurizon Therapeutics Limited (NUZ)
ORDINARY FULLY PAID
Health Care $50 Neurizon Invites Investors to Melbourne Briefing 2 Jul 2026 9:20AM $0.060 $0.066 risen by 10%
Neurizon Therapeutics Limited (NUZ)
ORDINARY FULLY PAID
Health Care $50 Change of Director's Interest Notice 1 Jul 2026 9:48AM $0.060 $0.066 risen by 10%
Neurizon Therapeutics Limited (NUZ)
ORDINARY FULLY PAID
Health Care $50 Proposed issue of securities - NUZ 30 Jun 2026 9:13AM $0.059 $0.066 risen by 11.86%
Neurizon Therapeutics Limited (NUZ)
ORDINARY FULLY PAID
Health Care $50 Notification of cessation of securities - NUZ 29 Jun 2026 4:31PM $0.059 $0.066 risen by 11.86%
Neurizon Therapeutics Limited (NUZ)
ORDINARY FULLY PAID
Health Care $50 New NUZ-001 Mechanistic Data Presented at BIO 2026 23 Jun 2026 11:25AM $0.061 $0.066 risen by 8.20%
Neurizon Therapeutics Limited (NUZ)
ORDINARY FULLY PAID
Health Care $50 Application for quotation of securities - NUZ 19 Jun 2026 11:15AM $0.066 $0.066 fallen by 0%

NUZ Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2025A -$16.59 -$3.40 117.50% 0.00 0.00 0.00% 0.0%
2024A -$5.79 -$1.50 54.00% 0.00 0.00 0.00% 0.0%
2023A -$3.25 -$1.00 88.70% 0.00 0.00 0.00% 0.0%

NUZ Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2023 A 2024 A 2025 A 2023 A 2024 A 2025 A 2023 A 2024 A 2025 A
Clarity Pharmaceuticals Ltd (CU6) $892M 0.3002 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Neuren Pharmaceuticals Limited (NEU) $2,071M -0.7857 0.0743 1.2000 70.2192 65.3600 29.7091 0.00% 0.00% 0.00%
Neurizon Therapeutics Limited (NUZ) $56M 1.1753 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%

NUZ Directors

Name Position Start Date
Mr Sergio Duchini Non-Executive Chairman, Non-Executive Director 17 May 2024
Dr Ross Murdoch Non-Executive Director 8 May 2026
Dr Kathryn(Katie) MacFarlane Non-Executive Director 17 Jun 2024
Mr Marcus Hughes Non-Executive Director 9 May 2024

Neurizon Therapeutics Limited (NUZ) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
30 Jun 2026 HUGHES, Marcus Buy Direct Shares 46,822 $0.058 $2,715.680
29 Jun 2026 HUGHES, Marcus Buy Direct Shares 3,340 $0.058 $193.720
26 Jun 2026 HUGHES, Marcus Buy Direct Shares 26,778 $0.058 $1,553.120

See all changes in directors' interest & trades for Neurizon Therapeutics Limited (NUZ) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

NUZ Management

Name Position
Daniel O'Connell Chief Financial Officer
Stefan Ross Company Secretary

NUZ Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Neurizon Therapeutics Limited (NUZ). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding Name
21,000,000 (7.49%) Hybrid Holdings Pty Ltd

NUZ Calendar of Events

Date Event
24 February 2027 Report (Interim)
25 August 2026 Report (Annual)
25 August 2026 Report (Prelim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.